Truist Financial analyst Jailendra Singh maintained a Hold rating on Doximity (DOCS – Research Report) today and set a price target of $31.00. The company’s shares closed yesterday at $23.74.
According to TipRanks, Singh is an analyst with an average return of -14.8% and a 32.97% success rate. Singh covers the Healthcare sector, focusing on stocks such as IQVIA Holdings, Evolent Health, and Progyny.
Doximity has an analyst consensus of Hold, with a price target consensus of $29.22, representing a 23.08% upside. In a report released today, Barclays also maintained a Hold rating on the stock with a $31.00 price target.
Based on Doximity’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $135.28 million and a net profit of $47.96 million. In comparison, last year the company earned a revenue of $115.26 million and had a net profit of $33.47 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Doximity (DOCS) Company Description:
Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.
Read More on DOCS:
